Immune checkpoint inhibitors: a new frontier in bladder cancer (Q38612706)

4 September 2017

title

Immune checkpoint inhibitors: a new frontier in bladder cancer (English)

1 reference

4 September 2017

4

Charles G Drake

1 reference

4 September 2017

Max Kates

1

1 reference

4 September 2017

Nikolai A Sopko

2

1 reference

4 September 2017

Hotaka Matsui

3

1 reference

4 September 2017

Noah M Hahn

5

1 reference

4 September 2017

Trinity J Bivalacqua

6

1 reference

4 September 2017

publication date

20 October 2015

1 reference

4 September 2017

published in

World Journal of Urology

1 reference

4 September 2017

volume

34

1 reference

4 September 2017

issue

1

1 reference

4 September 2017

page(s)

49-55

1 reference

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Prognostic and predictive impact of intra- and peritumoral immune infiltrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Immune infiltration in human tumors: a prognostic factor that should not be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Immune parameters affecting the efficacy of chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

B70 antigen is a second ligand for CTLA-4 and CD28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

CTLA-4 control over Foxp3+ regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Ipilimumab and its toxicities: a multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

The mechanism of action of BCG therapy for bladder cancer--a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Current clinical trials testing combinations of immunotherapy and radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Radiotherapy complements immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-015-1709-Y

Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.

21 January 2018

1 reference

12 December 2020

In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment

1 reference

12 December 2020

Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall

1 reference

12 December 2020

Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells

1 reference

12 December 2020

Identification of an alternative CTLA-4 ligand costimulatory for T cell activation

1 reference

12 December 2020

T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival

1 reference

12 December 2020

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

1 reference

12 December 2020

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer

1 reference

12 December 2020

Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin

1 reference

12 December 2020

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin

1 reference

12 December 2020

10.1007/S00345-015-1709-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

4 September 2017

1022340464

0 references

1 reference